sur The Vanguard Group, Inc. (isin : US12572Q1058)
The Vanguard Group Discloses Position in Avadel Pharmaceuticals
The Vanguard Group, Inc. has revealed its position in Avadel Pharmaceuticals plc through a Form 8.3 filing. This disclosure, submitted under Rule 8.3 of the Irish Takeover Panel Act, 1997, concerns entities with interests in relevant securities representing 1% or more.
The filing details The Vanguard Group's ownership of 5,852,019 ordinary shares of Avadel Pharmaceuticals, equivalent to a 6.01% stake. Additionally, transactions include the purchase of 445 shares and the sale of 19,587 shares, both at a unit price of 21.50 USD.
No cash-settled or stock-settled derivative positions were reported, and there are no indemnity or option arrangements, agreements, or understandings related to these securities. The disclosure highlights The Vanguard Group's ongoing interests in Avadel Pharmaceuticals as part of its investment strategy.
R. E.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de The Vanguard Group, Inc.